Passion & Purpose in Women’s Oncology
Company Overview
Founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, Sermonix Pharmaceuticals is a privately held biotechnology company focused on the development and commercialization of female-specific oncology products.
The ELAINE Study
The ELAINE Study is an open-label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2-) breast cancer with an acquired estrogen receptor 1 (ESR1) mutation and who have disease progression on an aromatase inhibitor (Al) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor.*
The primary objective is to evaluate the progression-free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation.
*AIs include Arimidex (anastrozole), Femara (letrozole), or Aromasin (exemestane). CDK 4/6 inhibitors include Kisqali (ribociclib), Ibrance (palbociclib), and Verzenio (abemaciclib).
All product names, trademarks, and registered trademarks are property of their respective owners.
